Overexpression of miRNA-9 Generates Muscle Hypercontraction Through Translational Repression of Troponin-T in *Drosophila melanogaster* Indirect Flight Muscles

Prasanna Katti, Divesh Thimmaya, Aditi Madan, and Upendra Nongthomba¹

Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore 560 012, India ORCID IDs: 0000-0002-6748-3460 (P.K.); 0000-0002-0616-5995 (U.N.)

ABSTRACT MicroRNAs (miRNAs) are small noncoding endogenous RNAs, typically 21-23 nucleotides long, that regulate gene expression, usually post-transcriptionally, by binding to the 3'-UTR of target mRNA, thus blocking translation. The expression of several miRNAs is significantly altered during cardiac hypertrophy, myocardial ischemia, fibrosis, heart failure, and other cardiac myopathies. Recent studies have implicated miRNA-9 (miR-9) in myocardial hypertrophy. However, a detailed mechanism remains obscure. In this study, we have addressed the roles of miR-9 in muscle development and function using a genetically tractable model system, the indirect flight muscles (IFMs) of Drosophila melanogaster. Bioinformatics analysis identified 135 potential miR-9a targets, of which 27 genes were associated with Drosophila muscle development. Troponin-T (TnT) was identified as major structural gene target of miR-9a. We show that flies overexpressing miR-9a in the IFMs have abnormal wing position and are flightless. These flies also exhibit a loss of muscle integrity and sarcomeric organization causing an abnormal muscle condition known as "hypercontraction." Additionally, miR-9a overexpression resulted in the reduction of TnT protein levels while transcript levels were unaffected. Furthermore, muscle abnormalities associated with miR-9a overexpression were completely rescued by overexpression of TnT transgenes which lacked the miR-9a binding site. These findings indicate that miR-9a interacts with the 3'-UTR of the TnT mRNA and downregulates the TnT protein levels by translational repression. The reduction in TnT levels leads to a cooperative downregulation of other thin filament structural proteins. Our findings have implications for understanding the cellular pathophysiology of cardiomyopathies associated with miR-9 overexpression.

Muscle contraction is crucially dependent on the proper assembly, maintenance, and function of myofibrils (Beall and Fyrberg 1991; Gordon *et al.* 2000). Myofibril assembly is a highly complex and

KEYWORDS

Drosophila melanogaster Troponin-T hypercontraction miRNA indirect flight muscles

coordinated process that requires the maintenance of appropriate stoichiometries of structural proteins and protein complexes, such as the actomyosin complex and the Tn–Tropomyosin complex (Laing and Nowak 2005; Firdaus *et al.* 2015). Defects, genetically caused or otherwise, in muscle development, structure, or function, result in a number of disorders and diseases, collectively referred to as myopathies (Charge and Rudnicki 2003; Selcen 2011; Gautam *et al.* 2015). Congenital myopathies, including genetic heart diseases, comprise a wide variety of muscle disorders that are mostly due to mutations in the contractile proteins (Chawla 2011; Selcen 2011). For example, mutations of cardiac TnT, α -Tm, and myosin cause hypertrophic cardiomyopathy (HCM) (Watkins *et al.* 1995; Karibe *et al.* 2001). Stoichiometric imbalances of structural proteins and altered isoform expression leading to myocardial damage are also seen in secondary cardiomyopathies, resulting from infection or other factors (Thierfelder *et al.* 1994; Watkins *et al.* 1996; Sisakian 2014). To achieve



Copyright © 2017 Katti *et al.*

doi: https://doi.org/10.1534/g3.117.300232

Manuscript received June 26, 2017; accepted for publication August 27, 2017; published Early Online September 1, 2017.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/ licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplemental material is available online at www.g3journal.org/lookup/suppl/ doi:10.1534/g3.117.300232/-/DC1.

¹Corresponding author: Department of Molecular Reproduction, Development and Genetics, GB03, Bioscience Bldg., Indian Institute of Science, Bangalore 560 012, India. E-mail: upendra@mrdg.iisc.ernet.in

the appropriate stoichiometric balances, many levels of regulation are required. While transcriptional regulation of these components is extremely important, the significance of the roles of microRNAs (miRNAs) in myopathies in general, and in hypertrophy in particular, are becoming increasingly recognized (Eisenberg and Psaty 2009; Parkes *et al.* 2015).

miRNAs are small noncoding endogenous RNAs, typically 22-30 nucleotide long, that exert subtle control over gene expression, transcriptionally or post-transcriptionally. This makes them an indispensable part of the regulatory network in almost all complex events in organisms ranging from plants to mammals, and even their viruses (Bartel and Chen 2004; Allen and Howell 2010; Carthew and Sontheimer 2009). In muscles, many miRNAs-including both the muscle-specific "myomiRs" such as miR-1, miR-133, and miR-206 (McCarthy 2008), as well as those more widely expressed, such as miR-24, miR-29, and miR-181 (Erriquez et al. 2013)-are involved in the regulation of both myoblast proliferation and differentiation (Chen et al. 2008). Importantly, the expression of several miRNAs is significantly altered during cardiac hypertrophy, myocardial ischemia, fibrosis, heart failure, and other cardiac myopathies (Latronico and Condorelli 2011; Oliveira-Carvalho et al. 2012). miR-9, a miRNA of recognized neural functions (Gladka et al. 2012; Krichevsky et al. 2003), reportedly plays a regulatory role in myocardial hypertrophy and is antagonistic to myocardin, a positive mediator of cardiac hypertrophy (Wang et al. 2010). In addition, miR-9 was implicated in the regulation of platelet-derived growth factor receptor-B, a regulator of cardiomyocyte angiogenesis (Zhang et al. 2011). Both studies reported downregulation of miR-9 upon activation of the hypertrophic response. Recently, clinical studies revealed that miR-9 expression levels are significantly lower in hypertensive patients as compared to healthy controls, and appear to be correlated with ventricular mass (Kontaraki et al. 2014). Thus, miR-9 appears to have more than one role in cardiac function. It is thus imperative to characterize its roles in the context of muscle development and function. There is high evolutionary conservation of the ultrastructure of striated muscles, their component proteins, and the mechanisms that regulate the assembly of sarcomeres and myofibril formation throughout vertebrates; similarly, there is substantial similarity between the muscles of invertebrates with complex locomotion (Taylor 2006). The Drosophila IFMs provide a good system with which to study muscle development, function, and associated diseases (Sparrow et al. 2008). This is particularly true with respect to the investigation of cardiomyopathic disorders, as the IFMs exhibit properties such as stretch activation and asynchronous contraction that are physiologically similar to those of cardiac muscles (Vigoreaux 2001). Specific mutations of the Drosophila contractile machinery (Kronert et al. 1995; Nongthomba et al. 2003), signaling cascades (Gajewski et al. 2006), and connective tissues (Pronovost et al. 2013) lead to muscle hypercontraction, associated with decreased structural integrity of the sarcomeres, which is similar to that seen in many myopathic conditions of higher organisms, including humans. In particular, the Drosophila miR-9a is an exact copy of the human miR-9 (Yuva-Aydemir et al. 2011).

In this study, we have investigated the regulatory role of miR-9a in *Drosophila* for IFM development and functioning. We show that *Drosophila* miR-9a plays a novel role in the regulation of TnT, a major structural protein, during myofibrillogenesis. This finding will lead to a better understanding of how human miR-9 may be involved in the pathogenesis of cardiac hypertrophy.

MATERIALS AND METHODS

Fly strains and crosses

All flies were maintained on standard cornmeal-agar-yeast medium. Canton-S was used as a control for most of the experiments unless specified. Crosses were performed at 25°, unless otherwise indicated. *UH3-Gal4* (X chromosome) expression from 36 hr after puparium formation (APF) onwards becomes IFM-specific (Singh *et al.* 2014). UAS-miR-9a [third chromosome, Bloomington *Drosophila* Stock Center (BDSC) #41138] and UAS-miR-SP-9a (third chromosome, kind gift from David Van Vactor, Harvard Medical School) were used for over-expression and knocking-down of miR-9a, respectively. UAS-SlsRNAi (third chromosome), UAS-mbcRNAi (third chromosome), and UAS-NeuralizedRNAi (third chromosome) were procured from the BDSC, and UAS-TnTRNAi (third chromosome) was from VDRC, Vienna (v27853). The green fluorescent protein (GFP) construct [sls-GFP (third chromosome)] has been described in Morin *et al.* (2001). All chromosomes and gene symbols are as mentioned in FlyBase (http:// flybase.org), unless specifically described.

Generation of UAS-TnT lacking the miR-9 binding site

Two transgenic fly lines [UAS-TnT (10a) and UAS-TnT (10b)] were generated for the overexpression of either the adult isoform (10a) or the pupal isoform (TnT-10b). The TnT transcripts (both 10a and 10b) were amplified using cDNA extracted from wild-type thoraces, using primers designed to target the 5'- and 3'-UTRs but to exclude the miR-9a binding site. The primers were also modified to incorporate EcoRI and KpnI restriction sites for subcloning into the pUAST overexpression vector (TnT FP with EcoRI site: 5'-GAACCGCAGAATTCGCTCC TAC-3', TnT RP with KpnI site: 5'-GTGAAGGAAAGTGGTACCC GAG-3'). The transcripts were cloned into a TA vector and the clones were screened for the presence of 10a or 10b transcripts using reverse primers specific for the alternatively spliced exon (TnT FP + TnT10a RP: 5'-TTGTGCGCTGAGTGAATC-3' and TnT FP + TnT10b RP: 5'-CGGTGTATTGCTCCTTCT-3'). The presence of the 10a or 10b transcripts in the respective clones was confirmed by sequencing. The sequenced clones and pUAST plasmid were digested with EcoRI and KpnI, the released inserts and cut pUAST vector were ligated, and the transgenic constructs were cloned and confirmed by sequencing. The construct, either pUAST-TnT-10a or pUAST-TnT-10b, along with л-helper plasmid (encoding for a transposase) was injected into embryos of white-eyed w1118 flies using the Olympus CK-X31- Narishige IM-9B microinjection system. The adult flies (G₀) that emerged were then crossed with white-eyed flies to produce the F1 generation. The transgenic flies were identified by their red eye phenotype.

Behavioral test

Flight ability was assayed using 2–3-d-old individual flies as described previously (Drummond *et al.* 1991) and the flies were categorized as up-flighted, horizontally-flighted, down-flighted, or flightless. Each fly was flight tested three times.

Polarized microscopy

For polarized microscopy, 2–3-d-old flies were bisected and processed using a protocol described previously (Nongthomba and Ramachandra 1999). Images were captured using an Olympus SZX12 microscope fitted with an Olympus C -5060 camera.

Hematoxylin and eosin staining

Hematoxylin and eosin staining of transverse sections of the adult thorax was done as previously described (Pantoja *et al.* 2013). Sections were mounted using Dibutylphthalate Polystyrene Xylene (DPX) mounting medium (Qualigens, Mumbai) and analyzed by light microscopy. Images were acquired using a Leica DFC300FX camera and processed using inbuilt software.

Confocal microscopy

The bisected fly hemithoraces were processed for immunohistochemical analysis as described previously (Rai *et al.* 2014). Following blocking, samples were treated differently depending on the type of analysis required.

Scanning electron microscopy (SEM)

SEM analysis of IFMs was used to visualize sarcomeric structure. Threed-old flies were dehydrated using an alcohol series (50, 70, 80, 90, 95, and 100%). Samples were incubated for 10 min in each dilution with the final dehydration step in 100% alcohol repeated twice. After twice incubating each sample in hexamethyldisilazane for 45 min, they were dried in a desiccator for 24 hr. The head, wings, abdomen, and legs were then removed, transferred to a glass slide, and bisected sagittally. Bisected thoraces were mounted onto an aluminum stub with carbon tape and surface coated by gold sputtering (20 nm thick film) using a Baltec sputter to avoid charging. A Zeiss, Ultra 55, Field Emission SEM with Secondary Electron Detector was used for imaging with an accelerating voltage of 2–5 keV and 8 mm working distance.

RNA and PCR

RNA was isolated from the IFMs of 2-3-d-old flies. IFMs were removed from the bisected thoraces at 4° and immersed in Trizol (Sigma). Next, RNA was extracted with the help of Trizol (Sigma) as per the manufacturer's protocol. cDNA was made using 1-2 µg of extracted RNA and a cDNA synthesis kit (Fermentas). The following primers were used: RP49 (FP: 5'-TTCTACCAGCTTCAAGATGAC-3', RP: -5'-GTGTATTCCGACCACGTTACA-3'); upheld (up) (FP: 5'-CTCG GGTGTCTCGGGCTCAC-3' RP: 5'-CTCGAACGAGAAGATCT GGA-3'); and Opa1-like (FP: 5'-AACGGTGGAGCCAGTTCTCG-3'; RP: 5'-TGATCTCCGTCTGCAGCGTC-3'). Quantitative PCR was carried out using DyNAmoTM HS SYBR green mix (F-410L; Thermo Scientific). Fluorescence intensities were recorded and analyzed in an ABI Prism 7900HT sequence detection system (SDS 2.1; Applied Biosystems). The relative changes in gene expression were estimated after normalization to the expression of a housekeeping gene, RP49. For semiquantitative PCR, reactions were set up using the 2× PCR Mastermix (Fermentas) and PCR amplification was carried out using a Mastercycler Nexus (Eppendorf).

Northern blotting

Detection of miRNA was carried out using the northern blotting protocol of Varallyay et al. (2008). RNA was extracted as described earlier, and quantified using a NanoDrop 1000 spectrophotometer (Thermo Scientific). Equal concentrations of samples were loaded on the gel. RNA bands were visualized under a UV transilluminator (JH BIO Innovations Pvt. Ltd.) and transferred onto a Nitrocellulose membrane (Millipore) by semidry transfer. Locked nucleic acid (LNA) Probe for miR-9a (5'-TCATACAGCTAGATAACCAAAGA-3') and control probe for U6snoRNA (5'-GTCATCCTTGCGCAGGGGCCATGC-3') was labeled using 1 μ l T4 polynucleotide kinase (PNK), 1 μ l [γ -³² P] ATP, and 2 µl PNK buffer, and the final volume was made up to 20 $\mu l.$ Following incubation at 37° for 60 min, the probe was purified using a Sephadex G-50 column. The membrane was washed twice with 0.5× TBE (Tris Borate-EDTA), allowed to cross-link under UV light for 60 sec, and then incubated at 40° for hybridization with LNA probe in 1× Perfect Hyb Plus buffer (Sigma) for 2–3 hr. The probed membrane was then washed three times with $2 \times$ SSC, 0.1% SDS buffer at 40° and exposed to photographic film. The exposed film was scanned using a Phosphor image scanner (GE Typhoon 9500).

Western blotting

Dissected adult IFMs were homogenized in sample buffer (312.5 mM Tris-HCl pH 6.8, 10% SDS, 0.5% Bromophenol Blue, 50% glycerol, and 25% β -mercaptoethanol) and denatured for 3 min at 95°. Samples were run on a 12.5% resolving gel and western blotting was carried out as described previously (Nongthomba *et al.* 2007). The primary antibodies used to detect specific proteins were: *Drosophila* anti-TnT raised in rat 1:1000 (gift from John Sparrow, UK), *Drosophila* anti-TnI raised in rabbit 1:1000 (gift from Alberto Ferrus, Spain), *Drosophila* anti-Flightin raised in rabbit 1:1000 (gift from John Sparrow, UK), and *Drosophila* anti- α -Tubulin raised in mouse 1:1000 (DHSB).

Bioinformatics analysis

miR-9a target prediction was done using five different target prediction software suites. These were Miranda (http://www.microrna.org/, Enright *et al.* 2003), Pic-Tar (http://pictar.bio.nyu.edu, Krek *et al.* 2005), the method used by Stark *et al.* (2003) (http://www.russell.embl.de/ miRNAs/), EMBL target prediction, and Target scan fly (http://www. targetscan.org/, Lewis *et al.* 2003). All five different algorithms predict miRNA targets, and hence their results should be nonoverlapping. We shortlisted targets recognized by three or more software suitesas significant matches. These shortlisted genes were cross-referenced to a *Drosophila* IFM microarray dataset (https://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc=GSE70252) to check for their expression levels in adult IFMs. The miR-9a targets thus obtained were then functionally annotated using DAVID (http://david.abcc.ncifcrf.gov/, Huang *et al.* 2008) and PantherDB software (http://www.pantherdb.org/about.jsp, Mi *et al.* 2005).

Data availability

We have provided the details of all the web addresses of data resources that we made use of in this study. Other data that support our findings have been included as Supplemental Material and are described in the *Results* section. Supplemental Figure legends are available in File S1.

RESULTS

Knockdown of miR-9a in the IFMs during myofibrillogenesis does not affect muscle structure and function

To investigate the role of miR-9a during myofibrillogenesis, we performed IFM-specific knockdown of miR-9a from 36 hr APF. Sarcomeres of the IFMs are established by an organized assembly of their structural proteins between 37 and 46 hr APF (Reedy and Beall 1993; Nongthomba et al. 2004). miR-9a is expressed in developing IFMs and the muscle attachment sites (Yatsenko and Shcherbata 2014), and expression is highly reduced in adult IFMs (Supplemental Material, Figure S1A). The knockdown of miR-9a during myofibril assembly had no detrimental effect on flight (Figure S1B). Flies with knockdown of miR-9a (UH3 > miR-SP-9a) exhibited close to normal flight ability, with 74.2% of flies capable of upward flight and 25.8% exhibiting horizontal flight (n = 31), which is similar to wild-type, where 80.6% of flies were up-flighted and 19.4% were horizontally-flighted (n = 31) (Figure S1B). Further, both wild-type (Figure S1C) and miR-9a knocked-down flies (Figure S1D) had six normal dorsal longitudinal muscles (DLM) fibers in each hemithorax with normal sarcomeric structures (Figure S1, C'-D").

Overexpression of miR-9a in the IFMs during myofibrillogenesis causes hypercontraction

To determine whether the inherently low expression of miR-9a during myofibrillogenesis (Figure S1A) is important for the critical roles of its

targets during this stage of muscle development, we overexpressed miR-9a in the IFMs throughout myofibrillogenesis. While miR-9a expression was barely detectable in wild-type IFMs, *UH3-Gal4*-mediated (Singh *et al.* 2014) miR-9a overexpression clearly increased miR-9a levels (Figure S1A) and adversely affected both wing posture and flight performance (Figure 1, A–B' and E).

The hemithoraces of wild-type flies showed presence of six DLMs (asterisks) with conventional sarcomeric structure, with well demarcated Z-discs (arrows) (Figure 1, C-C""). Whereas flies overexpressing miR-9a exhibited broken muscle fibers that appeared to be hypercontracted and pulled toward attachment sites (highlighted in Figure 1, D-D""), control wild-type adult hemithoraces showed the typical six wellorganized DLM fascicles (Figure 1C) and, at higher magnification, individuals showed well-arranged fibers (Figure 1C'). However, overexpression of miR-9a resulted in abnormal muscle and loss of myofibril integrity in the IFMs, with defects in sarcomeric organization and no organized Z-discs (Figure 1, D-D"). Unlike those of the wild-type flies (Figure S2, A and A'), flies overexpressing miR-9a had severe muscle disorganization (Figure S2B), with whole fascicles missing (black arrowheads, Figure S2B'). Flies of both sexes, overexpressing miR-9a, also exhibited a complete loss of flight ability [100% flightless (n =35)] unlike their control counterparts (+; +; UAS miR-9a/+) [90% up-flighted and 10% horizontally-flighted (n = 31)] (Figure 1E).

The loss of muscle integrity and sarcomeric structure caused by miR-9a overexpression (Figure 1, D-D") is very similar to the hypercontraction phenotype reported earlier (Nongthomba et al. 2003). This phenotype is usually associated with mutations in genes encoding sarcomeric structural proteins. It is well established in Drosophila IFMs that mutation in some of the structural proteins like TnT, Actin, and TnI can lead a the coordinated reduction in other thin filament proteins. These result in loss of sarcomeric structure and muscle hypercontraction, as a consequence of mis-regulated acto-myosin interaction (Nongthomba et al. 2003, 2004, 2007; Firdaus et al. 2015). The hypercontraction phenotype can be suppressed in flies with the MhcP401S mutation (Figure 1, G and G') (Nongthomba et al. 2003). This mutation is in the Actin binding head region of the myosin heavy chain, which prevents the interaction of the thin and thick filaments, thus reducing muscle contraction. Flies carrying MhcP401S mutation in the miR-9a overexpression background showed suppression of the muscle structural defects associated with the miR-9a overexpression (Figure 1, F-H). The DLMs and sarcomeric structure in adult flies (Figure 1, G and G') were comparable to those of wild-type controls (Figure 1, F and F'). Compared to flies with overexpression of miR-9a alone (Figure 1, H and H'), the hypercontraction suppressed flies possessed six DLMs (asterisks) (Figure 1G) with close to normal sarcomeric structures (Figure 1G', white arrow shows a Z-disc), confirming that the miR-9a muscle phenotype results from unregulated acto-myosin interactions.

To confirm that the muscle defects observed resulted directly from miR-9a overexpression in the IFMs during myofibrillogenesis, we studied the effect of suppressing miR-9a expression in the overexpression background. Knockdown of miR-9a in the overexpression background rescued the flight ability to levels similar to wild-type flies (Figure S1B). The adult flies had a normal arrangement and pattern of DLMs (Figure S2, D–E'). Thus, the hypercontraction was rescued and the IFMs showed ordered sarcomeres (Figure S2, D–E') in contrast to those with the phenotype from overexpression of miR-9a alone (Figure 1, D and D').

Overexpression of miR-9a results in downregulation of TnT

Hypercontraction results from the sarcomeres being unable to withstand the forces produced within them due to changes in the structural proteins of the sarcomere and/or their regulation. Therefore, we investigated if any such proteins are targets of miR-9a. Bioinformatics analysis identified 135 potential miR-9a targets that were then functionally annotated. Five different prediction programs were used (see Materials and Methods) and we chose only those predicted targets that were detected by three or more programs. Functional annotation revealed that these genes are involved in a variety of cellular and developmental functions such as transcriptional regulation, protein degradation, apoptosis, endocytosis, neuronal specification, imaginal disc development, etc., but that 29 genes are involved in muscle development (Figure 2A). All the putative miR-9a targets associated with muscle development proved to be involved in muscle function. Of these miR-9a targets in muscles, 4 genes are reported to be involved in larval muscle development, 19 in the development of pupal and adult muscles (Figure 2A) (Schnorrer et al. 2010), and 6 genes are associated with muscle development (Madan et al. 2017; https://www. ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70252). These putative targets are expressed in the IFMs as demonstrated using the Drosophila IFM microarray (https://www.ncbi.nlm.nih.gov/geo/query/ acc.cgi?acc=GSE70252) (Figure 2B).

Among the putative targets of miR-9a genes involved in muscle development and function is the *up* gene, which codes for all the TnT isoforms in Drosophila melanogaster. up showed a very high level of expression in adult IFMs (blue bar in Figure 2B, expression validated by real-time PCR in Figure 2C). The 3'-UTR of the up gene has the miR-9 binding site sequence (Figure 2D). Given that up mutations have been implicated in muscle hypercontraction (Nongthomba et al. 2003, 2007), we investigated whether miR-9a can cause the downregulation of TnT, possibly through binding to its target sequence at the 3'-UTR of TnT mRNA and suppressing the translational process as represented in Figure 2D. Indeed, there was a significant reduction in TnT protein levels (*P* value < 0.002) in the DLMs of flies overexpressing miR-9a compared to wild-type (Figure 2E). There was also a concomitant decrease in the levels of other structural proteins (which are not targets of miR-9a) that are part of the thin filament (Actin), including the Tn complex (TnI) (Figure S3A). On the other hand, Flightin, a thick filament component, was not reduced in flies overexpressing miR-9a compared to wild-type flies (Figure S3A). These results were expected since reduction of one thin filament protein is known to lead to a coordinated reduction of other thin filament proteins, but does not affect thick filament components (Nongthomba et al. 2004, 2007).

Repression of TnT by miR-9a is responsible for the hypercontraction phenotype

Since several putative miR-9a targets are important during muscle development, we asked whether the hypercontraction phenotype resulted directly from the downregulation of TnT by miR-9a or was due to the repression of other targets. First, we observed that the knockdown of TnT in IFMs during myofibrillogenesis generated a phenotype very similar to the overexpression of miR-9a. Knockdown of TnT resulted in the disruption of muscle structures (Figure S3, E and E'), which was comparable to the muscle defects seen in overexpression of miR-9a (Figure S3, F and F'). We further tested if the knockdown of some other predicted miR-9a targets can lead to similar defects in muscle structure and function. The downregulation of *neuralized*, an E3 ubiquitin ligase, failed to show any muscle defects (Figure S3, C and C'). Flies with a knockdown of Sallimus (Sls) showed six DLMs (Figure S3D). However, reduction in Sls, which is a structural component of the Z-disc, did result in some tearing of the sarcomeres (rectangle, Figure S3D'), but this was not comparable to the damage following miR-9a overexpression.



Figure 1 IFM-specific overexpression of miR-9a causes muscle hypercontraction. (A) Wild-type adult flies with normal wing posture. (A') Regular wing position along the body axis in a wild-type fly. (B) Adult flies overexpressing miR-9a have upheld wings. (B') Upright wing phenotype in a fly overexpressing mir-9a. (C) Polarized light micrograph of dissected wild-type adult hemithorax showing six DLMs (asterisks). (C' and C'') Adult myofibrils stained with Phalloidin-TRITC (F-actin) and SIs-GFP (arrows indicate Z-disc). (C"") SEM micrograph of wild-type myofibril (arrow indicates Z-disc). (D) Polarized light image of hemithorax of adult male with overexpression of miR-9a showing broken muscles (arrow) and clumped muscle (outlined in black and orange). (D' and D") Loss of sarcomeric structural integrity (box) in flies overexpressing miR-9a. (D") SEM micrograph showing absence of proper sarcomeres (box) after miR-9a overexpression (bar, 2 µm). (E) Flight assay of the miR-9a overexpression flies. (F) Images of wild-type hemithorax showing six DLMs (asterisks) under polarized light. (F') Phalloidin-TRITC-stained myofibril showing normal sarcomeric structure (arrow) in wild-type flies. (G) Adult flies carrying a myosin MhcP401S mutation in the overexpression of miR-9a background

н

Flight ability

H

To further confirm that that the muscle hypercontraction resulting from overexpressing miR-9a is a direct result of knockdown of TnT alone, we carried out a rescue of the muscle phenotype by overexpressing TnT devoid of the miR-9a binding site in flies with elevated levels of miR-9a in their IFMs. TnT transgenic lines were driven using UH3-Gal4 and shifted to 29° at 50-52 hr APF. Overexpression of transgenic TnT, either the TnT 10a or 10b isoform, devoid of the miR-9a binding sequence, restored TnT protein levels in these flies compared to flies overexpressing miR-9a alone (Figure 3A). Importantly, the restoration of TnT levels in the background of miR-9a overexpression completely rescued the hypercontraction phenotype. This was evidenced by the presence of six DLMs (Figure 3B') and the complete absence of any hypercontracted DLMs in the hemithoraces of these flies (Figure 3C). Further, the flight ability of these flies was also partially rescued: control flies [(UH3/+; +; +) Gal4 flies] were 100% up-flighted (n = 31); for TnT 10a, 19.6% of flies were horizontally-flighted, 28.2% down-flighted, and 52.2% flightless (n = 46); and for TnT 10b: 4.8% flies were up-flighted, 37.1% horizontally-flighted, 22.6% down-flighted, and 35.5% were flightless (n = 62); as compared to the flies with overexpression of miR-9a alone, of which were all flightless (n = 60) (Figure 3D). Both of these transgenic lines (TnT 10a and TnT 10b) showed almost complete restoration of muscle integrity and sarcomeric structure (Figure 4, B, B', D, and D') comparable to that of wild-type controls (Figure 4, A and A'), in stark contrast to the muscles in the flies overexpressing miR-9a (Figure 4, C and C').

These data argue that TnT is the major target of the miR-9a responsible for the muscle hypercontraction phenotype. We also confirmed that the rescue of the hypercontraction phenotype by expressing TnT isoforms in IFMs is indeed because of the restoration TnT and not due to Gal4 dilution. When *UH3-Gal4* was used to drive both UAS-miR-9a and UAS-GFP, the progeny still exhibited hypercontracted muscles in hemithoraces with loss of sarcomeric structure (Figure S4, B and B'), similar to the phenotype that results from driving UAS-miR-9a alone using *UH3-Gal4* (Figure 1, D and D').

DISCUSSION

The present study throws light on a new role played by miR-9a during muscle development and function. Previously, *Drosophila* miR-9a has only been shown to be involved in neuronal differentiation, wing margin patterning, and myotendinous junction formation (Biryukova *et al.* 2009; Bejarano *et al.* 2010; Yatsenko and Shcherbata 2014). We have now shown that miR-9a is involved in the translational regulation of TnT levels during sarcomeric assembly.

TnT is a major target of miR-9a during myofibrillogenesis in the IFMs

In general, miRNAs and their targets have been observed to exhibit mutually exclusive expression (Stark *et al.* 2005). While, miR-9a is strongly expressed in all developmental stages, its expression is reduced in adult flies, including the adult IFMs where its expression is much reduced compared to earlier developmental stages (Sempere *et al.* 2003). We have confirmed that miR-9a is barely detectable in adult IFMs (Figure S1A). These data suggest that the expression of some miR-9a targets could be required for IFM development and function.

We report here that overexpression of miR-9a causes a hypercontraction phenotype in the IFMs. We identified TnT, a structural component of

the thin filament of the sarcomere, as a major target for miR-9a in muscles, and have shown that miR-9a overexpression leads to repression of TnT and that this is sufficient to explain the IFM hypercontraction phenotype. In Drosophila, TnT is encoded by the up gene, is a key component in coordinating the Tn-Tm complex (Fyrberg et al. 1994; Nongthomba et al. 2007), and serves as an anchor for the other components of the complex which comprise TnI, TnC, and Tm (Gordon et al. 2000). Whereas the up^1 mutation is characterized by the absence of the adult IFM-specific TnT isoform, TnT-10a, resulting in hypercontraction (Nongthomba et al. 2007), the up¹⁰¹ mutation leads to increased calcium sensitivity and irregular acto-myosin interactions, which also cause hypercontraction, producing damaged muscles (Beall and Fyrberg 1991; Nongthomba et al. 2003, 2007). However, previously there has been no report that epigenetic regulation of TnT can also contribute to the maintenance of stoichiometric balance. To the best of our knowledge, this is the first report on the miRNA-mediated post-translational regulation of TnT.

Clearly, downregulation of TnT by miR-9a phenocopies the mutation in *up* via the same mechanism of stoichiometric imbalance that drives the mis-regulation of the acto-myosin interaction. Importantly, this demonstrates that not only defects in transcriptional control, but also the derailing of other regulatory processes such as miRNA-mediated control, can result in the same defects. Thus, our finding that miR-9a can alter levels of thin filament components via translational control of TnT demonstrates that miRNAs are not just "regulators of regulators," but can act as direct regulators in coordinating a complex process such as myofibrillar assembly. We show here that a major structural protein, TnT, can in fact be regulated by miRNA.

miR-9 is required for maintaining protein stoichiometry and may have implications in the etiology of myopathies

Studies on IFM mutants indicate that structural integrity of IFMs is highly dependent on interactions between thin and thick filaments, as well as the ratio of individual myofibrillar contractile components. Any change in gene dosage and corresponding protein stoichiometry in the thin filaments translates into defects in normal myofibrillar assembly leading to hypercontraction (Tansey *et al.* 1991; Nongthomba *et al.* 2003, 2007). This explains the myofibrillar defects that result from overexpression of TnT (Marco-Ferreres *et al.* 2005), Mhc (Cripps *et al.* 1994), and in most of the heterozygotes carrying mutations in genes encoding structural proteins (Prado *et al.* 1995; Gajewski and Saul 2010).

The phenomena of both hypercontraction and hypertrophy, although observably different, are both responses to the muscle contraction and the imbalance of structural proteins. In hypercontraction, the muscles show properly arranged sarcomeres during early development, but the subsequent uncontrolled acto-myosin interactions lead to stress and muscle tearing (Nongthomba *et al.* 2003). Hypertrophy, on the other hand, is characterized by an increase in muscle volume. For instance, myocardial hypertrophy is associated with cardiac remodeling where there is an increase of muscle wall thickness, but not through any increase in myocyte number (hyperplasia). However, cardiac hypertrophy is also a physiological response to stress induced by ischemia, mitochondrial defects, and mutations in sarcomeric components, etc. Importantly, mutations in the same gene orthologs that cause hypercontraction in *Drosophila* are the ones mutated in cardiac hypertrophy

show six DLMs (asterisks) in the hemithorax and (G') normal sarcomeres (arrows) in the myofibrils. (H) Polarized light image of hemithorax from flies with overexpression of miR-9a. (H') Abrogated sarcomeric structure (box) in the myofibrils of flies overexpressing miR-9a (bar, 2 μm). DLMs, dorsal longitudinal muscles; GFP, green fluorescent protein; IFM, indirect flight muscles; miR-9a, microRna-9a; SEM, scanning electron microscope; TRITC, tetramethylrhodamine.

Genes involved in Larval Muscle Morphology	Genes involved in IFM Morphology in adult/pupa					Genes with validated function in muscles	
Sls	nerfin1	Klp68D	SCAR	Lnk	CG14516	neur	Bx
htl	RhoGAP68 F	CG9000	qm	salm	sns	up	A2BP1
Akt1	mib2	Sra1	Coq2	mbc	Ebd1	opa1 like	mib2
CG4239	VAChT	babo	CG10617	Vha681			





Figure 2 Putative target genes of miR-9a that are involved in muscle development. (A) Lists of genes that are putative targets of miR-9a and their functions in muscles. The *upheld* gene that encodes TnT is highlighted in red (within blue box) (B) Expression profile of the putative miR-9a targets in the IFMs obtained from the microarray data from IFM of wild-type flies. The *upheld* gene showed highest expression in IFM (highlighted by the blue bar). (C) Relative expression of the target genes validated by real-time PCR. (D) Schematic representation of miR-9a binding site at 3'-UTR of *upheld* (TnT) and the mechanism of translation repression of TnT. (E) Quantification of the relative expression of TnT after miR-9a overexpression, using α -Tubulin as loading control (** signifies *P* value < 0.002). IFM, indirect flight muscles; miR-9a, microRna-9a; PCR, polymerase chain reaction; TnT, Troponin-T; UTR, untranslated region; NS, non-significant.

Α



Figure 3 Transgenic lines with overexpression of TnT (10a or 10b isoform) restore Troponin-T levels and rescue the muscle hypercontraction phenotype resulting from overexpression of miR-9a. (A) Western blots and the quantification of the relative expression of Troponin-T (loading control α -Tubulin). (B) Polarized light micrograph showing six normal DLMs following the overexpression of TnT-10a or (B') TnT-10b isoforms in the background of miR-9a overexpression. (B'') Polarized image showing hypercontracted muscles after miR-9a overexpression. (C) Quantification of the percentage of flies overexpressing miR-9a that present with hypercontraction phenotype after restoration of TnT levels. (D) Flight data for the flies overexpressing TnT 10a or 10b isoforms in the background of overexpression of miR-9a. ** signifies *P* value < 0.005, DLMs, dorsal longitudinal muscles; miR-9a, microRna-9a; NS, non-significant; PCR, polymerase chain reaction; TnT, Troponin-T.

patients as well. For example, mutations in the TnT gene are one of the predominant causes of hypertrophy (Seidman and Seidman 2001; Di Pasquale *et al.* 2012). Most of these TnT mutations exhibit increased calcium sensitivity and activation of muscle contractility (Harada and Potter 2004; Parvatiyar and Pinto 2015; Gilda *et al.* 2016), a similar pathogenesis to the hypercontraction produced by TnT mutants in *Drosophila* (Nongthomba *et al.* 2003, 2007). Viswanathan *et al.* (2014) have shown that the up^{101} mutation generates a muscle abnormality similar to human cardiomyopathy through sensitive calcium regulation in the *Drosophila* heart.

Vertebrate TnT (TNNT) has a vital role in the anchoring of Tn–Tm to Actin and is also essential for Ca⁺²-mediated activation and inhibition of acto-myosin activity during muscle contraction (Potter *et al.*

1995; Schiaffino and Reggiani 1996; Domingo *et al.* 1998; Perry 1998; Oliveira *et al.* 2000). Mutations in *TNNT* in *Caenorhabditis elegans* result in defects in embryonic body wall muscle contractions and sarcomere organization (Myers *et al.* 1996). Mutations in the cardiac isoform of TnT (TNNT2) are associated with familial HCM, dilated cardiomyopathy, or arthrogryposis (Thierfelder *et al.* 1994; Kamisago *et al.* 2000; Sehnert *et al.* 2002; Sung *et al.* 2003). TNNT2 was also found to be upregulated in cardiac hypertrophic or myocardial infarction conditions (Salic and De Windt 2012). However, there are still unanswered questions pertaining to the mechanisms by which cardiac TNNT2 upregulation is brought about during hypertrophy. Hence, the upstream players that regulate the level of cardiac TNNT2 during muscle development and function are very important.



Figure 4 Rescue of the loss of muscle integrity. (A) Polarized light micrograph of wild-type hemithorax with six DLMs. (A') Confocal microscopy image of wild-type muscles stained for F-actin along with SIs-GFP. The sarcomeres (box) and Z-discs (white arrows) are highlighted. (B and B') six DLMs (asterisks) and close to normal sarcomeric structure (box) with Z-discs (white arrows) in muscles of flies expressing TnT-10a in a miR-9a overexpression background. (C and C') Hypercontracted muscles (circled) and lack of sarcomeres (box) in muscles of flies overexpressing miR-9a. (D and D') Six DLMs (asterisks) and restored muscle structure (box) with Z-discs (white arrows) in flies overexpressing TnT-10b in a miR-9a overexpression background (Square Box) (Bar, 2 µm). DLMs, dorsal longitudinal muscles; GFP, green fluorescent protein; miR-9a, microRna-9a.

Drosophila miR-9a is identical to human miR-9 and the human TnT (TNNT) has significant homology to Drosophila TnT (Lagos-Quintana et al. 2001). Since miR-9a is capable of regulating TnT levels in Drosophila, it is possible that the human miR-9 may also play a role in regulating TNNT levels. Interestingly, sequence analysis of the human skeletal and cardiac isoforms of TNNT reveals that only the cardiac TNNT possesses the miR-9 binding site (Figure S4C) while the skeletal isoforms lack it. Incidentally, bioinformatic analysis failed to find a miR-9 target site in the mRNA sequence of mouse TNNT. It is important to note that the initial report of miR-9's role in muscle hypertrophy were from studies on mice (Wang et al. 2010), so miR-9a could be playing varied roles in different organisms. Our study suggests that miR-9a might be involved in specifically regulating the levels of cardiac TnT in humans. It would be interesting to know if the increase in cardiac TNNT that occurs in response to hypertrophic stimulus is mediated by miR-9. Many mutations of the human cardiac TnT give rise to the hypertrophic condition (Di Pasquale et al. 2012). However, cardiac hypertrophy is a genetically and clinically heterogeneous disorder and its etiology in many instances has not been determined (Gilda et al. 2016). The present study provides a plausible candidate in the form of miR-9 to explore in the etiology of idiopathic cardiomyopathies. It would be interesting to determine what represses miR-9 during myofibril assembly. Its continuous expression would be deleterious to myofibril assembly through its repression of the expression of very important structural proteins such as TnT. Taurine-upregulated gene-1 (TUG1) negatively regulates miR-9 in a human cancer cell line (Zhao and Ren 2016). Whether TUG1 or similar protein(s) are involved in muscle hypertrophy/hypercontraction and myofibril assembly requires further investigation.

ACKNOWLEDGMENTS

Our sincere thanks to John Sparrow (University of York), Jim O. Vigoreaux (University of Vermont), and Alberto Ferrus (Cajal Institute, Spain) for providing antibodies. The Bloomington *Drosophila* Stock

Center and the National Centre for Biological Sciences stock center, Bangalore, India kindly provided various fly lines. We extend our gratitude to David Van Vactor (Department of Cell Biology, Harvard Medical School) for the UAS-miR-Sp fly lines; Madhangi and John Sparrow for their critical comments and inputs; and anonymous reviewers for their comments and suggestions, which have led to substantial improvements in the manuscript. We also thank Kranthi at the Centre fro Nano Science and Engineering, Bangalore for help with scanning electron microscopy and Divya, Sima, Meenakshi Sen, and Deepti Bapat at the Indian Institute of Science (IISc) Confocal Facility for their patience and interest. We acknowledge the IISc, the Department of Science and Technology (DST FIST, 2008-2013 reference number SR/FST/LSII-018/2007), the University Grant Commission [UGC-SAP to the Department of Molecular Reproduction, Development and Genetics: reference number F.3-47/2009 (SAP-II)], and the Department of Biotechnology (DBT), Government of India (DBT-IISC Partnership Program for Advanced Research in Biological Sciences and Bioengineering Sanction Order number. DBT/BF/ PRIns/2011-12/IISc/28.9.2012) for financial assistance.

LITERATURE CITED

- Allen, E., and M. D. Howell, 2010 miRNAs in the biogenesis of trans-acting siRNAs in higher plants. Semin. Cell Dev. Biol. 21: 798–804.
- Bartel, D. P., and C. Z. Chen, 2004 Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat. Rev. Genet. 5: 396–400.
- Beall, C. J., and E. Fyrberg, 1991 Muscle abnormalities in *Drosophila mel-anogaster heldup* mutants are caused by missing or aberrant troponin-I isoforms. J. Cell Biol. 114: 941–951.
- Bejarano, F., P. Smibert, and E. C. Lai, 2010 miR-9a prevents apoptosis during wing development by repressing Drosophila LIM-only. Dev. Biol. 338: 63–73.
- Biryukova, I., J. Asmar, H. Abdesselem, and P. Heitzler, 2009 Drosophila mir-9a regulates wing development via fine-tuning expression of the LIM only factor, dLMO. Dev. Biol. 327: 487–496.

- Carthew, R. W., and E. J. Sontheimer, 2009 Origins and mechanisms of miRNAs and siRNAs. Cell 136: 642–655.
- Charge, S., and M. A. Rudnicki, 2003 Fusion with the fused: a new role for interleukin-4 in the building of muscle. Cell 113: 422–423.
- Chawla, J., 2011 Stepwise approach to myopathy in systemic disease. Front. Neurol. 2: 49.
- Chen, Y., N. K. Lee, J. D. Zajac, and H. E. MacLean, 2008 Generation and analysis of an androgen-responsive myoblast cell line indicates that androgens regulate myotube protein accretion. J. Endocrinol. Invest. 31: 910–918.
- Cripps, R. M., K. D. Becker, M. Mardahl, W. A. Kronert, D. Hodges *et al.*, 1994 Transformation of *Drosophila melanogaster* with the wild-type myosin heavy-chain gene: rescue of mutant phenotypes and analysis of defects caused by overexpression. J. Cell Biol. 126: 689–699.
- Di Pasquale, G., S. Urbinati, E. Perugini, and S. Gambetti, 2012 Interactions between cardiovascular and cerebrovascular disease. Curr. Treat. Options Neurol. 14: 557–593.
- Domingo, A., J. Gonzalez-Jurado, M. Maroto, C. Diaz, J. Vinos *et al.*,
 1998 Troponin-T is a calcium-binding protein in insect muscle: in vivo phosphorylation, muscle-specific isoforms and developmental profile in *Drosophila melanogaster*. J. Muscle Res. Cell Motil. 19: 393–403.
- Drummond, D. R., E. S. Hennessey, and J. C. Sparrow, 1991 Characterisation of missense mutations in the Act88F gene of *Drosophila melanogaster*. Mol. Gen. Genet. 226: 70–80.
- Eisenberg, M. S., and B. M. Psaty, 2009 Defining and improving survival rates from cardiac arrest in US communities. JAMA 301: 860–862.
- Enright, A. J., B. John, U. Gaul, T. Tuschl, C. Sander *et al.*, 2003 MicroRNA targets in Drosophila. Genome Biol. 5: R1.
- Erriquez, D., G. Perini, and A. Ferlini, 2013 Non-coding RNAs in muscle dystrophies. Int. J. Mol. Sci. 14: 19681–19704.
- Firdaus, H., J. Mohan, S. Naz, P. Arathi, S. R. Ramesh *et al.*, 2015 A cisregulatory mutation in troponin-I of Drosophila reveals the importance of proper stoichiometry of structural proteins during muscle assembly. Genetics 200: 149–165.
- Fyrberg, C., H. Parker, B. Hutchison, and E. Fyrberg, 1994 Drosophila melanogaster genes encoding three troponin-C isoforms and a calmodulin-related protein. Biochem. Genet. 32: 119–135.
- Gajewski, K. K., and J. P. Saul, 2010 Sudden cardiac death in children and adolescents (excluding sudden infant death syndrome). Ann. Pediatr. Cardiol. 3: 107–112.
- Gajewski, K. M., J. Wang, and R. A. Schulz, 2006 Calcineurin function is required for myofilament formation and troponin I isoform transition in Drosophila indirect flight muscle. Dev. Biol. 289: 17–29.
- Gautam, R., S. Vanga, A. Madan, N. Gayathri, U. Nongthomba *et al.*,
 2015 Raman spectroscopic studies on screening of myopathies. Anal. Chem. 87: 2187–2194.
- Gilda, J. E., X. Lai, F. A. Witzmann, and A. V. Gomes, 2016 Delineation of molecular pathways involved in cardiomyopathies caused by Troponin-T mutations. Mol. Cell. Proteomics 15: 1962–1981.
- Gladka, M. M., P. A. da Costa Martins, and L. J. De Windt, 2012 Small changes can make a big difference microRNA regulation of cardiac hypertrophy. J. Mol. Cell. Cardiol. 52: 74–82.
- Gordon, A. M., E. Homsher, and M. Regnier, 2000 Regulation of contraction in striated muscle. Physiol. Rev. 80: 853–924.
- Harada, K., and J. D. Potter, 2004 Familial hypertrophic cardiomyopathy mutations from different functional regions of troponin T result in different effects on the pH and Ca2+ sensitivity of cardiac muscle contraction. J. Biol. Chem. 279: 14488–14495.
- Huang, J. C., B. J. Frey, and Q. D. Morris, 2008 Comparing sequence and expression for predicting microRNA targets using GenMiR3. Pac. Symp. Biocomput. 2008: 52–63.
- Kamisago, M., S. D. Sharma, S. R. DePalma, S. Solomon, P. Sharma *et al.*, 2000 Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N. Engl. J. Med. 343: 1688–1696.
- Karibe, A., L. S. Tobacman, J. Strand, C. Butters, N. Back *et al.*, 2001 Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium

binding to troponin, abnormal myosin cycling, and poor prognosis. Circulation 103: 65–71.

- Kontaraki, J. E., M. E. Marketou, E. A. Zacharis, F. I. Parthenakis, and P. E. Vardas, 2014 MicroRNA-9 and microRNA-126 expression levels in patients with essential hypertension: potential markers of target-organ damage. J. Am. Soc. Hypertens. 8: 368–375.
- Krek, A., D. Grun, M. N. Poy, R. Wolf, L. Rosenberg *et al.*, 2005 Combinatorial microRNA target predictions. Nat. Genet. 37: 495–500.
- Krichevsky, A. M., K. S. King, C. P. Donahue, K. Khrapko, and K. S. Kosik, 2003 A microRNA array reveals extensive regulation of microRNAs during brain development. RNA 9: 1274–1281.
- Kronert, W. A., P. T. O'Donnell, A. Fieck, A. Lawn, J. O. Vigoreaux *et al.*, 1995 Defects in the Drosophila myosin rod permit sarcomere assembly but cause flight muscle degeneration. J. Mol. Biol. 249: 111–125.
- Lagos-Quintana, M., R. Rauhut, W. Lendeckel, and T. Tuschl, 2001 Identification of novel genes coding for small expressed RNAs. Science 294: 853–858.
- Laing, N. G., and K. J. Nowak, 2005 When contractile proteins go bad: the sarcomere and skeletal muscle disease. Bioessays 27: 809–822.
- Latronico, M. V., and G. Condorelli, 2011 MicroRNAs in hypertrophy and heart failure. Exp. Biol. Med. (Maywood) 236: 125–131.
- Lewis, B. P., I. H. Shih, M. W. Jones-Rhoades, D. P. Bartel, and C. B. Burge, 2003 Prediction of mammalian microRNA targets. Cell 115: 787–798.
- Madan, A., D. Thimmaiya, A. Franco-Cea, M. Aiyaz, P. Kumar et al., 2017 Transcriptome analysis of IFM-specific actin and myosin nulls in Drosophila melanogaster unravels lesion-specific expression blueprints across muscle mutations. Gene 631: 16–28.
- Marco-Ferreres, R., J. J. Arredondo, B. Fraile, and M. Cervera, 2005 Overexpression of troponin T in Drosophila muscles causes a decrease in the levels of thin-filament proteins. Biochem. J. 386: 145–152.
- McCarthy, J. J., 2008 MicroRNA-206: the skeletal muscle-specific myomiR. Biochim. Biophys. Acta 1779: 682–691.
- Mi, H., B. Lazareva-Ulitsky, R. Loo, A. Kejariwal, J. Vandergriff *et al.*, 2005 The PANTHER database of protein families, subfamilies, functions and pathways. Nucleic Acids Res. 33: D284–D288.
- Morin, X., R. Daneman, M. Zavortink, and W. Chia, 2001 A protein trap strategy to detect GFP-tagged proteins expressed from their endogenous loci in Drosophila. Proc. Natl. Acad. Sci. USA 98: 15050–15055.
- Myers, C. D., P. Y. Goh, T. S. Allen, E. A. Bucher, and T. Bogaert, 1996 Developmental genetic analysis of troponin T mutations in striated and nonstriated muscle cells of *Caenorhabditis elegans*. J. Cell Biol. 132: 1061–1077.
- Nongthomba, U., and N. B. Ramachandra, 1999 A direct screen identifies new flight muscle mutants on the Drosophila second chromosome. Genetics 153: 261–274.
- Nongthomba, U., M. Cummins, S. Clark, J. O. Vigoreaux, and J. C. Sparrow, 2003 Suppression of muscle hypercontraction by mutations in the myosin heavy chain gene of *Drosophila melanogaster*. Genetics 164: 209– 222.
- Nongthomba, U., S. Clark, M. Cummins, M. Ansari, M. Stark et al., 2004 Troponin I is required for myofibrillogenesis and sarcomere formation in Drosophila flight muscle. J. Cell Sci. 117: 1795–1805.

Nongthomba, U., M. Ansari, D. Thimmaiya, M. Stark, and J. Sparrow, 2007 Aberrant splicing of an alternative exon in the Drosophila troponin-T gene affects flight muscle development. Genetics 177: 295–306.

- Oliveira, D. M., C. R. Nakaie, A. D. Sousa, C. S. Farah, and F. C. Reinach, 2000 Mapping the domain of troponin T responsible for the activation of actomyosin ATPase activity. Identification of residues involved in binding to actin. J. Biol. Chem. 275: 27513–27519.
- Oliveira-Carvalho, V., V. O. Carvalho, M. M. Silva, G. V. Guimaraes, and E. A. Bocchi, 2012 MicroRNAs: a new paradigm in the treatment and diagnosis of heart failure? Arq. Bras. Cardiol. 98: 362–369.
- Pantoja, M., K. A. Fischer, N. Ieronimakis, M. Reyes, and H. Ruohola-Baker, 2013 Genetic elevation of sphingosine 1-phosphate suppresses dystrophic muscle phenotypes in Drosophila. Development 140: 136–146.
- Parkes, J. E., P. J. Day, H. Chinoy, and J. A. Lamb, 2015 The role of microRNAs in the idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 27: 608–615.

- Parvatiyar, M. S., and J. R. Pinto, 2015 Pathogenesis associated with a restrictive cardiomyopathy mutant in cardiac troponin T is due to reduced protein stability and greatly increased myofilament Ca²⁺ sensitivity. Biochim. Biophys. Acta 1850: 365–372.
- Perry, S. V., 1998 Troponin T: genetics, properties and function. J. Muscle Res. Cell Motil. 19: 575–602.
- Potter, J. D., Z. Sheng, B. S. Pan, and J. Zhao, 1995 A direct regulatory role for troponin T and a dual role for troponin C in the Ca²⁺ regulation of muscle contraction. J. Biol. Chem. 270: 2557–2562.
- Prado, A., I. Canal, J. A. Barbas, J. Molloy, and A. Ferrus, 1995 Functional recovery of troponin I in a Drosophila heldup mutant after a second site mutation. Mol. Biol. Cell 6: 1433–1441.
- Pronovost, S. M., M. C. Beckerle, and J. L. Kadrmas, 2013 Elevated expression of the integrin-associated protein PINCH suppresses the defects of Drosophila melanogaster muscle hypercontraction mutants. PLoS Genet. 9: e1003406.
- Rai, M., P. Katti, and U. Nongthomba, 2014 Drosophila Erect wing (Ewg) controls mitochondrial fusion during muscle growth and maintenance by regulation of the Opa1-like gene. J. Cell Sci. 127: 191–203.
- Reedy, M. C., and C. Beall, 1993 Ultrastructure of developing flight muscle in Drosophila. I. Assembly of myofibrils. Dev. Biol. 160: 443–465.
- Salic, K., and L. J. De Windt, 2012 MicroRNAs as biomarkers for myocardial infarction. Curr. Atheroscler. Rep. 14: 193–200.
- Sisakian, H., 2014 Cardiomyopathies: evolution of pathogenesis concepts and potential for new therapies. World J. Cardiol. 6: 478–494.
- Schiaffino, S., and C. Reggiani, 1996 Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Physiol. Rev. 76: 371–423.
- Schnorrer, F., C. Schonbauer, C. C. Langer, G. Dietzl, M. Novatchkova *et al.*, 2010 Systematic genetic analysis of muscle morphogenesis and function in Drosophila. Nature 464: 287–291.
- Sehnert, A. J., A. Huq, B. M. Weinstein, C. Walker, M. Fishman *et al.*, 2002 Cardiac troponin T is essential in sarcomere assembly and cardiac contractility. Nat. Genet. 31: 106–110.
- Seidman, J. G., and C. Seidman, 2001 The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104: 557–567.
- Selcen, D., 2011 Myofibrillar myopathies. Neuromuscul. Disord. 21: 161– 171.
- Sempere, L. F., N. S. Sokol, E. B. Dubrovsky, E. M. Berger, and V. Ambros, 2003 Temporal regulation of microRNA expression in Drosophila melanogaster mediated by hormonal signals and broad-complex gene activity. Dev. Biol. 259: 9–18.
- Singh, S. H., P. Kumar, N. B. Ramachandra, and U. Nongthomba, 2014 Roles of the troponin isoforms during indirect flight muscle development in Drosophila. J. Genet. 93: 379–388.
- Sparrow, J., S. M. Hughes, and L. Segalat, 2008 Other model organisms for sarcomeric muscle diseases. Adv. Exp. Med. Biol. 642: 192–206.
- Stark, A., J. Brennecke, R. B. Russell, and S. M. Cohen, 2003 Identification of Drosophila microRNA targets. PLoS Biol. 1: E60.

- Stark, A., J. Brennecke, N. Bushati, R. B. Russell, and S. M. Cohen, 2005 Animal microRNAs confer robustness to gene expression and have a significant impact on 3'UTR evolution. Cell 123: 1133–1146.
- Sung, S. S., A. M. Brassington, P. A. Krakowiak, J. C. Carey, L. B. Jorde *et al.*, 2003 Mutations in TNNT3 cause multiple congenital contractures: a second locus for distal arthrogryposis type 2B. Am. J. Hum. Genet. 73: 212–214.
- Tansey, T., J. R. Schultz, R. C. Miller, and R. V. Storti, 1991 Small differences in Drosophila tropomyosin expression have significant effects on muscle function. Mol. Cell. Biol. 11: 6337–6342.
- Taylor, M. V., 2006 Comparison of muscle development in Drosophila and vertebrates, pp. 169–203 in *Muscle Development in Drosophila*, edited by Sink, H., Landes Bioscience, Georgetown, TX.
- Thierfelder, L., H. Watkins, C. MacRae, R. Lamas, W. McKenna *et al.*, 1994 Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 77: 701–712.
- Varallyay, E., J. Burgyan, and Z. Havelda, 2008 MicroRNA detection by northern blotting using locked nucleic acid probes. Nat. Protoc. 3: 190– 196.
- Vigoreaux, J. O., 2001 Genetics of the Drosophila flight muscle myofibril: a window into the biology of complex systems. Bioessays 23: 1047–1063.
- Viswanathan, M. C., G. Kaushik, A. J. Engler, W. Lehman, and A. Cammarato, 2014 A Drosophila melanogaster model of diastolic dysfunction and cardiomyopathy based on impaired troponin-T function. Circ. Res. 114: e6–e17.
- Wang, K., B. Long, J. Zhou, and P. F. Li, 2010 miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J. Biol. Chem. 285: 11903–11912.
- Watkins, H., J. G. Seidman, and C. E. Seidman, 1995 Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy. Hum. Mol. Genet. 4: 1721–1727.
- Watkins, H., C. E. Seidman, J. G. Seidman, H. S. Feng, and H. L. Sweeney, 1996 Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action. J. Clin. Invest. 98: 2456–2461.
- Yatsenko, A. S., and H. R. Shcherbata, 2014 Drosophila miR-9a targets the ECM receptor Dystroglycan to canalize myotendinous junction formation. Dev. Cell 28: 335–348.
- Yuva-Aydemir, Y., A. Simkin, E. Gascon, and F. B. Gao, 2011 MicroRNA-9: functional evolution of a conserved small regulatory RNA. RNA Biol. 8: 557–564.
- Zhang, J., V. Chintalgattu, T. Shih, D. Ai, Y. Xia *et al.*, 2011 MicroRNA-9 is an activation-induced regulator of PDGFR-beta expression in cardiomyocytes. J. Mol. Cell. Cardiol. 51: 337–346.
- Zhao, X., and G. Ren, 2016 LncRNA taurine-upregulated gene 1 promotes cell proliferation by inhibiting microRNA-9 in MCF-7 cells. J. Breast Cancer 19: 349–357.

Communicating editor: H. Salz